# Kenneth W Merrell

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 54 papers | 472 citations | 12 h-index | 20 g-index |
| 59 ext. papers | 700 ext. citations | 3.4 avg, IF | 3.51 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 54 | Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 488-497 | 4 | 55 |
| 53 | Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. *Radiotherapy and Oncology*, **2017**, 123, 376-381 | 5.3 | 54 |
| 52 | A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. *Advances in Radiation Oncology*, **2019**, 4, 63-69 | 3.3 | 43 |
| 51 | Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes. *Annals of Surgery*, **2019**, 269, 663-670 | 7.8 | 35 |
| 50 | Left ventricular function after noninvasive cardiac ablation using proton beam therapy in a porcine model. *Heart Rhythm*, **2019**, 16, 1710-1719 | 6.7 | 24 |
| 49 | Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. *Practical Radiation Oncology*, **2020**, 10, e16-e26 | 2.8 | 24 |
| 48 | Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review. *Abdominal Radiology*, **2016**, 41, 2061-77 | 3 | 23 |
| 47 | A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 820-828 | 4 | 18 |
| 46 | Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. *Annals of Surgery*, **2018**, 268, 289-295 | 7.8 | 18 |
| 45 | Utility of F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. *Journal of Thoracic Oncology*, **2017**, 12, 121-128 | 8.9 | 16 |
| 44 | Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. *Advances in Radiation Oncology*, **2018**, 3, 314-321 | 3.3 | 15 |
| 43 | Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC. *Advances in Radiation Oncology*, **2019**, 4, 422-428 | 3.3 | 13 |
| 42 | A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal Cancer. *Practical Radiation Oncology*, **2019**, 9, 410-417 | 2.8 | 12 |
| 41 | Radiation and immunotherapy: emerging mechanisms of synergy. *Journal of Thoracic Disease*, **2020**, 12, 7011-7023 | 2.6 | 11 |
| 40 | Spot-scanned pancreatic stereotactic body proton therapy: A dosimetric feasibility and robustness study. *Physica Medica*, **2016**, 32, 331-42 | 2.7 | 11 |
| 39 | Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. *Radiotherapy and Oncology*, **2020**, 146, 29-36 | 5.3 | 10 |
| 38 | Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 561-70 | 4 | 10 |

| | | | |
|---|---|---|---|
| 37 | Radiation Therapy for Retroperitoneal Sarcomas: Influences of Histology, Grade, and Size. *Sarcoma*, **2018**, 2018, 7972389 | 3.1 | 9 |
| 36 | Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. *Brachytherapy*, **2019**, 18, 306-312 | 2.4 | 8 |
| 35 | Catheter-free ablation of infarct scar through proton beam therapy: Tissue effects in a porcine model. *Heart Rhythm*, **2020**, 17, 2190-2199 | 6.7 | 7 |
| 34 | FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery. *Practical Radiation Oncology*, **2017**, 7, e531-e541 | 2.8 | 6 |
| 33 | Radiation biology considerations of proton therapy for gastrointestinal cancers. *Journal of Gastrointestinal Oncology*, **2020**, 11, 225-230 | 2.8 | 5 |
| 32 | Intracranial long-term complications of radiation therapy: an image-based review. *Neuroradiology*, **2021**, 63, 471-482 | 3.2 | 5 |
| 31 | Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. *Annals of Thoracic Surgery*, **2018**, 106, 1541-1547 | 2.7 | 5 |
| 30 | Patterns of inguinal lymph node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation. *Radiotherapy and Oncology*, **2020**, 149, 128-133 | 5.3 | 4 |
| 29 | Clinical Implementation of Preoperative Short-Course Pencil Beam Scanning Proton Therapy for Patients With Rectal Cancer. *Advances in Radiation Oncology*, **2020**, 5, 865-870 | 3.3 | 3 |
| 28 | Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series. *Canadian Journal of Neurological Sciences*, **2020**, 47, 525-530 | 1 | 3 |
| 27 | Stereotactic body radiotherapy for primary and metastatic liver tumors - the Mayo Clinic experience. *Journal of Radiosurgery and SBRT*, **2016**, 4, 133-144 | 0.4 | 3 |
| 26 | Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. *Journal of Gastrointestinal Oncology*, **2020**, 11, 1408-1420 | 2.8 | 2 |
| 25 | Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. *Advances in Radiation Oncology*, **2021**, 6, 100675 | 3.3 | 2 |
| 24 | Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry Study. *Practical Radiation Oncology*, **2021**, 11, e63-e69 | 2.8 | 2 |
| 23 | Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. *Translational Lung Cancer Research*, **2021**, 10, 965-980 | 4.4 | 2 |
| 22 | Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) non-small cell lung cancer. *Advances in Radiation Oncology*, **2017**, 2, 12-18 | 3.3 | 1 |
| 21 | Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. *Nature Reviews Clinical Oncology*, **2019**, 16, 521-522 | 19.4 | 1 |
| 20 | Low Dose, Single Fraction, Whole Lung Irradiation for Extramedullary Hematopoiesis Associated with Myelofibrosis with Myeloid Metaplasia. *Blood*, **2015**, 126, 2820-2820 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 19 | A multicenter study of trimodality therapy for patients 75 years and older with esophageal cancer.. *Journal of Clinical Oncology*, **2019**, 37, 131-131 | 2.2 | 1 |
| 18 | Focused versus conventional radiotherapy in spinal oncology: is there any difference in fusion rates and pseudoarthrosis?. *Journal of Neuro-Oncology*, **2022**, 1 | 4.8 | 1 |
| 17 | Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. *Frontiers in Oncology*, **2021**, 11, 651119 | 5.3 | 1 |
| 16 | Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience. *Clinical and Translational Radiation Oncology*, **2021**, 28, 17-23 | 4.6 | 1 |
| 15 | Multi-institutional Comparison of Intensity Modulated Photon Versus Proton Radiation Therapy in the Management of Squamous Cell Carcinoma of the Anus. *Advances in Radiation Oncology*, **2021**, 6, 100744 | 3.3 | 1 |
| 14 | A Multi-Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Therapy for Esophageal Cancer. *Practical Radiation Oncology*, **2021**, 11, e415-e425 | 2.8 | 1 |
| 13 | Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.. *Translational Lung Cancer Research*, **2022**, 11, 173-187 | 4.4 | 1 |
| 12 | Predictors of lymphopenia in esophageal cancer patients receiving photon or proton radiation therapy: A dosimetric analysis.. *Journal of Clinical Oncology*, **2019**, 37, 147-147 | 2.2 | 0 |
| 11 | Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. *Radiotherapy and Oncology*, **2021**, 158, 246-252 | 5.3 | 0 |
| 10 | Single institution toxicity of definitive chemoradiation and maintenance durvalumab in locally advanced non-small cell lung cancer.. *Journal of Clinical Oncology*, **2021**, 39, e20554-e20554 | 2.2 | 0 |
| 9 | Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. *Journal of Gastrointestinal Oncology*, **2021**, 12, 2275-2286 | 2.8 | 0 |
| 8 | Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity. *International Journal of Particle Therapy*, **2021**, 8, 41-50 | 1.5 | 0 |
| 7 | Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. *Translational Lung Cancer Research*, **2021**, 10, 3713-3736 | 4.4 | 0 |
| 6 | Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience. *Frontiers in Oncology*, **2020**, 10, 392 | 5.3 | |
| 5 | Does the dural resection bed need to be irradiated? Patterns of recurrence and implications for postoperative radiotherapy for temporal lobe gliomas. *Neuro-Oncology Practice*, **2021**, 8, 190-198 | 2.2 | |
| 4 | Pre-treatment pulmonary function testing as a predictor of cardiopulmonary toxicity in esophageal cancer patients treated with trimodality therapy.. *Journal of Clinical Oncology*, **2019**, 37, 121-121 | 2.2 | |
| 3 | HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation.. *Journal of Clinical Oncology*, **2021**, 39, 239-239 | 2.2 | |
| 2 | Evaluation of Pretreatment Magnetic Resonance Elastography for the Prediction of Radiation-Induced Liver Disease. *Advances in Radiation Oncology*, **2021**, 6, 100793 | 3.3 | |

# List of Publications

| | | |
|---|---|---|
| 1 | Independent predictors of vertebral compression fracture following radiation for metastatic spine disease.. *Journal of Neurosurgery: Spine*, **2022**, 1-7 | 2.8 |